Table 1. Survival analysis according to T-lymphocyte markers using different cutoff levels in HER2-positive cancer defined by category of HER2 status from the Kaplan-Meier plotter.

Split patients	CD4				CD8				FOXP3
	No. of patients*	HR†	95% CI	Log-rank p	No. of patients*	HR†	95% CI	Log-rank p	No. of patients*	HR†	95% CI	Log-rank p
Lower quartile	42:126	0.59	0.34–1.02	0.058	42:126	0.73	0.41–1.29	0.275	39:111	1.03	0.56–1.90	0.929
Lower tertile	55:113	0.6	0.36–1.02	0.058	55:113	0.83	0.48–1.43	0.492	50:100	1.09	0.61–1.95	0.781
Median	84:84	0.99	0.59–1.67	0.983	84:84	1.04	0.61–1.74	0.896	75:75	1.01	0.58–1.75	0.973
Upper tertile	113:55	1.19	0.69–2.05	0.534	113:55	0.56	0.31–1.03	0.060	100:50	0.67	0.36–1.24	0.202
Upper quartile	126:42	1.49	0.84–2.64	0.168	128:40	0.51	0.25–1.03	0.057	112:38	0.64	0.32–1.27	0.198

HER2=human epidermal growth factor receptor 2; HR=hazard ratio; CI=confidence interval.

^*Number of patients was presented as patients having low expression versus those having high expression; ^†Hazard ratio of patients having high expression of biomarker.